Synopsis of key findings
This clinical trial demonstrated that betahistine is no more effective than a placebo to treat primary tinnitus. The THI score improvement was minimal and without significant difference between study groups. Additionally, the secondary endpoint, covariate adjustment, and per-protocol analysis provided similar results and side effects were without difference across both groups.